Zealand Q1 ’20 Earnings Update; Xeris Partners with Clinigen

Two diabetes-related news items have ben observed: Zealand hosted its Q1 ’20 earnings call and Xeris announced it has entered into an agreement with Clinigen for ex-US Gvoke distribution. Importantly, Zealand disclosed BI is now pursuing its GLP-1/GCG dual agonist (BI 456906) for NASH. Below, FENIX provides highlights and insights from the respective news items.

About The Author

Matthew Maryniak

President of Fenix Group International

Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.

If you receive our email blasts, you already have an account.

Purchase Blast$599.00

You can read the article’s full content online after purchase.